Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 29;10(1):641.
doi: 10.1186/s13104-017-2950-9.

Urine cell-free microRNA as biomarkers for transitional cell carcinoma

Gil A Geva  1 , Ilan Gielchinsky  2 , Nina Aviv  1 , Klaas E A Max  3 , Ofer N Gofrit  2 , Devorah Gur-Wahnon  1 , Iddo Z Ben-Dov  4
Affiliations

Urine cell-free microRNA as biomarkers for transitional cell carcinoma

Gil A Geva et al. BMC Res Notes. .

Abstract

Objective: MicroRNA (miRNA) are short nucleotide strands with a regulatory function in the cell. Several miRNAs have been shown to be useful as biomarkers for different neoplasms. The aim of this project was to assess whether levels of miRNA in cell free urine could be used as a biomarker in transitional cell carcinoma (TCC).

Results: cDNA libraries were produced based on small RNAs in urine samples of fourteen TCC patients and twenty healthy volunteers. Resulting reads were deep sequenced on Illumina HiSeq sequencer with the intent of characterizing cell free urine miRNA profiles. A statistically significant difference was found for a single miRNA; miR-210 was > sixfold higher in the TCC group compared to the control group. Furthermore, we were able to produce a diagnostic score by summing of standardized levels of overexpressed miRNA. This score was considerably higher in TCC patients with a sensitivity of 0.93, specificity of 0.76 and negative predictive value > 0.97.

Keywords: Biomarkers; Extracellular RNA; Transitional cell carcinoma; Urothelial carcinoma; microRNA.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Levels of the upregulated miRNA clusters in the TCC patients’ samples vs. healthy volunteers’ samples, expressed as base-2 logarithm of the normalized counts (box plots)
Fig. 2
Fig. 2
Upregulated miRNA-based diagnostic score values are higher in the TCC vs. healthy subjects (a box plots), and perform well in discrimination of patients from controls (b receiver operating characteristics (ROC) curve)
See this image and copyright information in PMC

References

    1. Lotan Y. Clinical presentation, diagnosis, and staging of bladder cancer. Waltham: UpToDate.com; 2014.
    1. Rouprêt M, et al. Guidelines on urothelial carcinomas of the upper urinary tract. Eur Urol. 2015;68:868–879. doi: 10.1016/j.eururo.2015.06.044. - DOI - PubMed
    1. Hanke M, et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol Semin Orig Investig. 2010;28:655–661. doi: 10.1016/j.urolonc.2009.01.027. - DOI - PubMed
    1. An F, et al. Silencing of miR-370 in human cholangiocarcinoma by allelic loss and interleukin-6 induced maternal to paternal epigenotype switch. PLoS ONE. 2012;7:e45606. doi: 10.1371/journal.pone.0045606. - DOI - PMC - PubMed
    1. Huang X, Le Q, Giaccia AJ. MiR-210—micromanager of the hypoxia pathway. Trends Mol Med. 2010;16:230–237. doi: 10.1016/j.molmed.2010.03.004. - DOI - PMC - PubMed

MeSH terms